HomeBUSINESS
BUSINESS

Olaparib Gets Orphan Status for BRCA-Mutated Breast Cancer
(Oct.3.2017)

The Japan arm of AstraZeneca said on September 29 that its anticancer agent olaparib was granted orphan drug designation by the Japanese health ministry on the same day for BRCA mutation-positive inoperable/recurrent breast cancer ...
(LOG IN FOR FULL STORY)

News Calendar